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Abstract
Microfluidic ‘organ-on-a-chip’ devices hold great potential for better mimicking the continuous flow microenvironment 
experienced by tissue and cells in vivo, thereby ensuring realistic transport of nutrients and elimination of waste products. 
However, the mass transport of oxygen, which arguably is the most critical nutrient due to its inherently low solubility in 
water, is rarely assessed. To this aim, the suitability of various precision-cut liver slice (PCLS) microfluidic devices for the 
defined maintenance of oxygen mass transport were evaluated using COMSOL simulations, leading to the development of 
a novel, optimised design to provide defined in vivo oxygenation conditions within an organ-on-a-chip system. Simulations 
found that the proposed device was capable of maintaining 43% of the tissue slice volume within the physiological range of 
the liver against 18% for the best performing literature device. The optimal device architecture derived from the modelling 
was then fabricated and its operation confirmed with an LDH assay. These simulation results form the basis for a greater 
understanding of not just the challenges involved in designing organ-on-a-chip devices, but also highlight issues that would 
arise from the incorporation of additional organs, as research progresses towards complete human-on-a-chip model systems.
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1 Introduction
Pharmaceutical companies face great challenges in their 
endeavour to translate biological knowledge into novel 
drugs. It has been estimated that it takes upwards of 12 years 
to get a drug into market with an associated cost of about 
$12 billion dollars (Visk 2015). However, the road that phar-
maceutical companies have to travel to develop and release 
a drug successfully into the market is filled with challenges. 
Novel drug candidates face exceedingly high attrition rates 
of 90% when attempting to transition from clinical trials into 
the market (Visk 2015).
The liver is the primary organ attributed to many of these 
drug development failures since its metabolic specialisation 
renders it susceptible to drug-induced liver injury (DILI) 
(Patel et al. 2012; Kullak-Ublick et al. 2017; Iorga et al. 
2017). This occurs even though preclinical liver model sys-
tems (microsomes, hepatocytes, liver slices and animals) 
for a long time have constituted an integral part in the drug 
development pipeline. The failure of current platforms to 
allow eventual drug failures to slip through the net and pro-
ceed into clinical trials can be partly attributed to their lack 
of predictability arising from a lack of relevant components 
and pathways in the particular models as well as shortcom-
ings of the interrogation platform (Esch et al. 2014). In 
addition, there is a move to reduce animal use therefore, 
the demand from the pharmaceutical industry for better pre-
clinical in vitro system which more accurately predict the 
in vivo properties of drug candidates is extremely strong 
(Usta et al. 2015).
Organ-on-a-chip devices couple well-established bio-
logical model systems with the flow control and microen-
vironment manipulation offered by microfluidics to create 
better in vivo mimicking conditions. Much attention has 
been directed at utilising cell-lines (Cheng et al. 2006; Rod-
rigues et al. 2008; Ges and Baudenbacher 2010a,b; Hiatt 
et al. 2012; Weltin et al. 2014) or artificial cell aggregates, 
i.e., spheroids (Misun et al.2015, 2016; Ortega-Prieto et al. 
2018). However, these do not fully reflect the inherent 
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complexity of native organs which feature a multitude of 
distinct cell types, extracellular matrix and spatial organi-
sation. The liver is comprised of at least 7 distinct cell 
types (Gupta 2018) and more than 15 different extracellu-
lar matrix components (Bedossa and Paradis 2003). Thus, 
some groups have investigated organ biopsies in the form 
of precision-cut tissue slices (PCTS) for organ-on-a-chip 
devices, as these are directly obtained from the target organ 
(Blake et al. 2007; Rambani et al. 2009; Midwoud et al. 
2011; Chang et al. 2012; Astolfi et al. 2016) and, therefore, 
more accurately maintain the composition and organisation 
of the cell types and extracellular matrix. As compared to 
cell-monolayers, the tissue slices contain multiple layers and 
typically range in 100–250 μm thickness (Graaf et al. 2007). 
These relatively large dimensions imply that the penetration 
and depletion of oxygen in the tissue slice should be given 
consideration.
Oxygenation is well established as an important culture 
parameter for maintaining both the function and viability of 
biological systems (Camp and Capitano 2007). Although 
the oxygen content in the air is approximately 21%, the nor-
moxic conditions in vivo are tissue specific, ranging from 
as low as 0% in the bone marrow to 14% in well-perfused 
tissues such as the liver, heart and lungs (Ivanovic 2009; 
Adams 2012). In vivo the task of oxygenating tissues is 
undertaken by the oxygen binding hemoglobins, which 
circumvent the inherently low solubility of molecular oxy-
gen in water, which at 37 °C under standard atmospheric 
conditions is approximately 0.2 mM. The hemoglobin acts 
as an oxygen reservoir that replenishes the pool of soluble 
oxygen available for cellular consumption. In vitro, however, 
researchers mostly rely on high carbogen atmospheres, e.g. 
95%  O2 and 5%  CO2 to provide PCLS with an adequate sup-
ply of oxygen during culture. The importance of mimicking 
in vivo liver oxygen tensions (0.042–0.091 mM) has been 
highlighted via improved maintenance of cellular functions 
such as those involved in drug metabolising pathways (Jun-
germann and Keitzmann 1996; Jungermann and Kietzmann 
2000; Camp and Capitano 2007; Guo et al. 2017). However, 
little attention has been given to assessing the mass transport 
of oxygen in tissue slice microfluidic devices, wherein, the 
low media perfusion contact length to tissue volume ratio 
constitute a challenge both in terms of ensuring adequate 
oxygen and maintaining regions within a narrow window 
matching those found in vivo. Here, simulations were per-
formed to assess tissue oxygenation within several published 
liver-on-chip devices and, based on these findings, an opti-
mised device for maintenance of PCTS for liver-on-chip was 




Computer simulations were carried out in COMSOL Mul-
tiphysics 5.2 (COMSOL AB). Mesh convergence assess-
ments were performed on simulation geometries to deter-
mine appropriate mesh settings in each of the simulations. 
COMSOL’s physics for laminar flow and transport of diluted 
chemical species were employed for the simulations. The 
computed flows were calculated based on the assumption 
of a non-compressible fluid and with a no-slip boundary 
condition imposed on both the surfaces of the tissue slice 
and the wall domains.
The transport of nutrients in the simulation was described 
by the generic diffusion equation as given in Eq. 1, R is a 
reaction term, u⃗ is the velocity field and c is the concentra-
tion of the species.
To account for the consumption of various species, reac-
tion kinetics were implemented. The consumption of oxy-
gen was calculated with Michaelis–Menten reaction kinetics 
(Eq. 2), Vmax is the maximum consumption rate, c the con-
centration and Km is the Michaelis–Menten constant.
Furthermore, to account for cellular processes such as 
necrosis, which would occur when the local oxygen con-
centrations drop below a certain threshold under which cells 
would no longer be considered viable, a  factor was imple-
mented based on COMSOL’s smoothed Heaviside func-
tion [flc1hs (step, scale)] (Buchwald 2011). The function 
eliminates the reaction term for the cellular consumption by 
going to zero when C < Ccrit is valid and being equal to one 
for Ccrit, thus ensuring that cells which occupy a region of 
space below the Ccrit will not consume oxygen. The necrotic 
oxygen tension threshold Ccrit for the liver tissue was 2.64 
 10–3 mol  m−3 based on Mattei et al. (Chang et al. 2014). A 
maximum consumption rate of 0.059 mol  s−1  m−3 and a 
Michaelis–Menten constant of 0.0033 mol  m−3 were uti-
lised in the simulations based on consumption measurements 
performed by Buerk et al. with implantable micro-oxygen 
electrodes in liver and brain slices (Buerk and Saidel 1978).
Due to the inherently low flow permeability of tissue, 
this transport mechanic was neglected apart from in those 
devices wherein geometrical constraints force the flow 
directly through the tissue. These utilised a porosity of 0.4 
and a permeability of 1·10–11  m2 as derived from brain tis-















Microfluidics and Nanofluidics           (2021) 25:35  
1 3
Page 3 of 12    35 
permeability parameters could be gathered for instance 
where matrigel was used to encapsulate tissues, it was 
assigned the same values as the tissue slices.
The mesh settings and the mesh convergence assessment 
used to establish these for the simulations are described in 
ESI1.
2.2  Device design and fabrication
The microfluidic chip device, designed based on the findings 
from the COMSOL modelling, consisted of a top layer made 
from polystyrene (PS), a tissue layer made from PS and a 
bottom layer from Poly(methyl methacrylate) (PMMA) 
(Fig. 1 and ESI2). Two PDMS gas exchange membranes 
were held in close proximity to the tissue slice, which was 
harboured within a tissue unit (Fig. 2).
The top layer was 4 mm thick and featured CNC milled 
holes (Datron M7, Datron, Germany) for bolts (4.35 mm 
diameter), holes for inlet and outlet tubing (2.35 mm), holes 
for purge valves (2 mm) and a “breathing window” for the 
PDMS gas exchange (4 mm) (figure S2.1). A PDMS assem-
bly consisting of a 3 mm thick PDMS slab which had been 
through-holed with a 4 mm punch and attached to a 50 μm 
thick layer was aligned and attached to the top layer so that 
the 3 mm PDMS through-hole matched the breathing win-
dow opening in the top layer. The middle tissue layer was 
0.8 mm thick with a 28 mm long and 4.2 mm wide through-
cut fluidic channel with a central 13.5 mm wide circular 
and 0.525 mm deep recess for the positioning of the tissue 
unit carrier harbouring the PCLS (fig S2.2). To enclose the 
bottom part of the through-cut fluidic channel a 50 μm thick 
PDMS layer was attached to the tissue layer. The bottom 
layer was 9.5 mm thick with 4.35 mm wide bolt holes and 
with a 0.6 mm deep oval recess for accurate positioning of 
the tissue layer (figure S2.3). The top PS and bottom PMMA 
layer parts had 4 mm wide centrally located holes serving as 
PDMS breathing windows for the PCLS.
The tissue unit featured two 50 μm thick nylon meshes 
with 60 μm pore size laser-cut to size from a Falcon cell 
strainer membrane (Thermo Fisher Scientific) as well as two 
Fig. 1  Schematic of the PDMS 
sandwich device featuring the 
three main components of the 
chip. (Tissue unit is not shown)
Fig. 2  CAD illustration of the tissue unit assemblies and manu-
factured device. a Exploded view of a tissue unit consisting of two 
50-μm thick nylon meshes and two separate PMMA layers. A nylon 
mesh membrane was bonded directly onto each PMMA layer by chlo-
roform vapour exposure, to create the two individual parts of the tis-
sue unit. b Photo of the complete chip with red dye solution pumped 
through to test for leakages
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separate PMMA layers (Fig. 2, ESI3). These PMMA layers 
were cut into inner and outer frames and the nylon mesh was 
bonded directly onto these by chloroform vapour exposure. 
The tissue layer incorporated a side step for positioning of 
the PCLS, thus simultaneously ensuring that the tissue slice 
was maintained at a mid-height position and directly beneath 
the openings of the PDMS breathing windows. The device 
was fully assembled as laid out in ESI4.
To maintain the applied atmosphere, a 2 L glass vessel 
was fitted with two gas line adapters and ports for suba rub-
ber septa (Chemglass Life Sciences) (Fig. 3). Incoming gas 
was directed through a gas washer to humidify the inflow 
into the vessel, whereafter the gas would exit via the second 
gas line adapter into a purging vessel. The humidification of 
the gas inflow was done to prevent the potentially adverse 
evaporation of liquid through the PDMS membranes of 
the chip and the silicone rubber gas exchange tubing (ID 
0.6 mm, wall thickness 0.35 mm) (Hilltop Products Ltd). 
The glass vessel was housed within a commercial egg incu-
bator (COVATUTTO) operating at a temperature of 37 °C.
2.3  PCLS experiments on‑chip
2.3.1  Chemicals and buffers
PDMS was obtained from Dow Chemical Company. Wil-
liams medium E (WME) was bought from Life Technologies 
Ltd, fetal bovine serum and KCl were bought from Thermo 
Fisher Scientific. D-Glucose, NaOH and NaCl were pur-
chased from VWR. Agarose,  CaCl2,  KH2PO4  MgSO4 and 
HEPES were sourced from Sigma Aldrich.
Krebs–Henseleit buffer (KHB) for  tissue slicing was 
prepared according to Graaf et al. (Graaf et al. 2010). The 
1 × KHB buffer solution had final concentrations of 2.5 mM 
 CaCl2, 118 mM NaCl, 1.1 mM  MgSO4, 1.2 mM  KH2PO4, 
25 mM  NaHCO3, 25 mM D-Glucose, 10 mM HEPES. The 
solution was placed on ice and oxygenated with a gas mix-
ture consisting of 95%  O2 and 5%  CO2 and adjusted to a pH 
of 7.4 with NaOH.
2.3.2  Process to cut and insert liver slice
The animal work was performed under ethics application 
U2017 002 as approved by the ethical committee at the Uni-
versity of Hull. The mice were all females and derived from 
the C57BL/6 J and Rhobtb3 ± strains. The sacrifice was per-
formed by  CO2 inhalation, whereafter the liver was excised 
and immediately submerged into ice-cold oxygenated (95% 
 O2 and 5%  CO2) KHB. Preparation and slicing of liver tissue 
was done according to the protocol of Graaf et al. (2010).
Fresh liver tissue as obtained after sacrifice was placed 
on a cutting mat consisting of a Petri-dish filled with 3% 
agarose. The tissue was covered with ice-cold KHB. A lobe 
of the liver was cut away and blotted on a piece of tissue to 
remove water whereafter it was glued onto the specimen 
stage with a Loctite Liquid Superglue 3G cyanoacrylate 
adhesive (Henkel Ltd). The glue was given a minute to set 
whereafter it was mounted on the Vibratome 1200S (Leica) 
stage in a buffer tray filled with ice-cold oxygenated KHB. 
The vibratome settings for the slicing were a slice thickness 
of 150 μm and a blade clearance angle of 18° and feed speed 
of 0.08 mm  s−1. Based on mass transport considerations this 
particular thickness was selected as it is in the low end of 
the reported PCLS thickness values in the literature (Graaf 
et al. 2007).
The precision cut tissue sheets (see ESI5) were trans-
ferred from the tray with a spatula. Slices were either used 
to generate uniformly sized cylindrical PCLS with a 4 mm 
Fig. 3  Schematic of the experi-
mental setup used in the PCLS 
incubation experiments with the 
proposed device
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biopsy punch (Miltex) or used directly without any addi-
tional processing. The punching was performed by placing 
the tissue sheets flat on a 3% agarose Petri-dish filled with 
ice-cold oxygenated KHB. The PCLS were subsequently 
transferred with a cut plastic Pasteur pipette into a 50-mL 
tube filled with 5-mL ice-cold oxygenated KHB until use. 
After use tools were cleaned with EtOH and autoclaved 
(126 °C, 11 min).
2.3.3  Experimental process
Microfluidic chips were either autoclaved or thoroughly 
flushed with EtOH before each experiment, and chip and 
workspace surfaces were wiped down with EtOH to mini-
mise the possibility of bacterial contamination. The cell 
medium consisted of WME supplemented with FBS and 
HEPES to final concentrations of 10% and 10 mM, respec-
tively. For antibiotics, penicillin, streptomycin, and neomy-
cin were added at final concentrations of 50 and 100 μg  L−1, 
respectively. WME was selected since it a frequently used 
medium for PCLS (Graaf et al. 2010).
The medium was loaded into 20-mL or 50-mL syringes 
in a class two biological safety cabinet. The syringes were 
mounted on a syringe pump and connected to the microflu-
idic chips, which were housed inside an egg incubator unit 
set to maintain a temperature of 37 °C (ESI6). The length 
of the tubing was chosen so that the surface areas were suf-
ficiently large to heat up the medium from room tempera-
ture to 37 °C before it reached the tissue. One PCLS was 
then loaded into the tissue cavity of each microfluidic chip 
and the perfusion was initiated. The first collection of the 
effluent from the individual chips was done at the 2 h time 
point, whereafter all subsequent ones were collected at 24-h 
intervals.
Conventional tissue slice incubation on PICMORG50 
well plate inserts (EMD Millipore Corporation) in six-well 
plates were run in parallel with the microfluidic experiments 
for comparison. Three slices were used for each well insert 
with 1.1 mL WME and medium changes were performed on 
the same schedule as for the microfluidic chips.
2.3.4  Measurements
Lactate dehydrogenase (LDH) was used as a biomarker for 
cell death by monitoring the release of this enzyme into 
the effluent. LDH content in tissue lysates was additionally 
assessed to determine the viability of the PCLS at the end 
of the incubations. Individual PCLS were collected and ini-
tially fragmented into smaller bits by vigorous pippetting 
in 500 μL 1%(v/v) Triton X-100 and were then left on ice 
for 45 min. Solutions were then cleared by centrifugation at 
12,000g for 10 min, after which the supernatants were col-
lected and diluted 1:16 with water to get within the linear 
range of the LDH assay. The LDH was measured with a 
 Pierce™ LDH cytotoxicity assay kit at wavelength of 490 nm 
according to the manufacturer’s guidelines.
3  Results and discussion
3.1  COMSOL modelling of published devices
COMSOL simulations were conducted to investigate how 
the transport efficiency of oxygen would theoretically com-
pare across different published platforms, as well as with the 
herein proposed chip design. Several PCLS-based microflu-
idic devices have been published (Midwoud et al. 2010,2011; 
Sivashankar et al. 2012; Wu et al. 2012). These devices can 
broadly be separated into three different design categories 
(Fig. 4): (a) a PDMS flow-through perfusion approach, in 
which fluid is pushed through a tissue slice (Midwoud et al. 
2010, 2011), (b) an intra-perfusion approach, in which pierc-
ing needles deliver a flow of medium directly into the core of 
the tissue slice and (Sivashankar et al. 2012), (c) an approach 
employing perfusion from a narrow channel above or below 
the tissue (Wu et al. 2012).
3.2  PDMS flow‑through approach (Midwoud et al. 
2010, 2011)
The device designed by Midwoud et al. featured a 4 mm 
wide and 250 μm thick PCLS encased in a Matrigel slab held 
together by two 10-μm thick porous polycarbonate mem-
branes. The flow at a rate of 10 μL  min−1 entered the chip 
through a single inlet at the top, passed through the tissue 
slice and then exited via a single outlet. For gas exchange 
purposes, 250-μm thick PDMS membranes were attached at 
the top and bottom of the device with the entire chip being 
placed in an incubator containing a 95% oxygen atmosphere.
The COMSOL simulation of oxygen concentrations 
within the device reveal that the fluid is fully saturated 
(1017 mM) in the upper half of the device near the inlet and 
top gas exchange membrane region as shown in (Fig. 5a, 
b). However, as the flow progresses downward towards the 
tissue slice, a significant oxygen concentration gradient is 
established in the vertical direction. Near the bottom of 
the chip, which harboured the second PDMS gas exchange 
membrane, the partially depleted oxygen in the flow stream 
can be observed to rapidly equilibrate again with the external 
oxygen atmosphere as it progresses towards the outlet.
The results highlight the geometrical dependence of gas 
exchange membranes. For oxygen mass transport through a 
PDMS membrane to occur, the liquid immediately adjacent 
to the PDMS/liquid interface must have an oxygen satura-
tion < 100%. Furthermore, in this particular chip design 
approach, it is crucial to position the tissue slice of a certain 
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diameter precisely in the flow cylinder of the same diam-
eter; any potential geometrical mismatch would lead to fluid 
being directed around rather than through the porous tissue 
slice.
One potential issue with this design approach, wherein 
the flow is guided through the slice, is that it is likely to 
cause changes to the tissue morphology via the formation 
of distinct flow paths going through the tissue slices. This 
has been observed in chips utilising the same approach. 
Rambani et al. found that flow paths and associated cell 
death in their vicinities occurred in brain slices when flow 
rates of greater than 20 μL   h−1 were utilised (Rambani 
et al. 2009). This flow rate corresponded to a flow veloc-
ity of 7.86 ×  10–4  mm   s−1, significantly lower than the 
1.3 ×  10–2 mm  s−1 utilised by Midwoud et al. In comparison, 
the interstitial flow in vivo, which runs between the capil-
lary/lymphatic systems and drain tissues, has a flow velocity 
within the range of 0.1–2 ×  10–4 mm  s−1 (Khong et al. 2007). 
In addition, as these flow paths represent areas exhibiting 
a significantly lower flow resistance compared to the bulk 
porous volume of the surrounding tissue mass, a dispropor-
tionately higher magnitude of the flow will go through these 
formed flow paths, than would have done so otherwise. This 
would render void one of the underlying assumptions of the 
simulations, namely that the properties of the tissue volume 
can be modeled as being a uniform isotropic mass. How-
ever, it would be possible to accommodate such paths in a 
model granted that these generated flow paths are uniformly 
scattered throughout the tissue volume and provided that the 
change in permeability was known.
Piercing needles (Sivashankar et al. 2012) were utilised in 
the second design approach to deliver nutrients directly into 
the core of the tissue to overcome mass transport limitations 
in thick tissue slices. The device employed seven needles 
with an outer and inner diameter of 300 μm and 150 μm, 
respectively, arranged in a pattern with a central needle and 
the remaining equally spaced radially at a 2.5 mm distance. 
The needles delivered a combined flow rate of 1 mL  min−1 
of air saturated medium (225 μM) into a tissue slice of a 
diameter of 8 mm and a thickness of 1 mm dimensions. The 
effects of this approach can be been seen from the simulation 
(Fig. 5c, d). Highly oxygenated regions were found within 
a radius of approximately 1 mm from each of the needle 
injection points, as viewable when plotting the concentration 
along the radius of the tissue at mid-height (Fig. 5d). Within 
this region, the initial 500 μm experienced a mass transport 
influx of oxygen which was so significant that it was capa-
ble of overcoming the drain from the cellular consumption 
rate by maintaining the tissue volume at near fully saturated 
levels. However, mass transport limitations readily become 
evident further away from the needle sources where the oxy-
gen tension levels can be observed to drop down below the 
critical threshold value.
The perfusion channel (Wu et al. 2012) geometry was 
based around maintaining a 4  mm3 liver section with deliv-
ery nutrients at 2 μL  min−1 via a narrow channel (190 μm 
Fig. 4  Schematic drawings of 
microfluidic incubation chips 
utilised for liver tissue experi-
ments. a Cylindrical PDMS 
flow-through perfusion PDMS 
chip wherein the PCLS is 
encased in matrigel. b Needle 
intra-perfusion chip. c Glass 
chip based on perfusing the tis-
sue from above and beneath
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wide and 70 μm deep) running beneath the tissue cham-
ber. From the oxygen consumption simulations (Fig. 5e, 
f) it can be observed that when the saturated flow enters 
the tissue chamber and comes into contact with the tis-
sue section, the oxygen becomes gradually consumed as 
it progresses further towards the outlet. This gives rise 
to the formation of spatio-specific mass transport regions 
near the tissue interface, with the steepest oxygen concen-
tration gradients and highest fluxes occurring at the front 
of the tissue near the chamber inlet. Less steep oxygen 
gradients are formed at the top and in particular rear areas 
of the tissue piece, due to lower flow velocities and pro-
gressively depleting oxygen concentrations. A plot of the 
oxygen tension levels, within the tissue at the mid-height 
line (Fig. 5f) reveals that adequate oxygen concentrations 
are only attained until a depth of approximately 100 μm, 
thus leaving the vast majority of the tissue volume within 
an oxygen depleted zone.
3.3  COMSOL modelling of proposed PDMS 
sandwich device
To overcome oxygen transport limitations and better main-
tain the PCLS within the in vivo concentration range care-
ful consideration must be given to materials and geometry. 
Based on the findings from the aforementioned COMSOL 
simulations, a novel microfluidic device was devised to 
achieve this.
Based on the fact that oxygen is the most limiting com-
ponent of cell medium, due to its inherently low solubil-
ity, a geometry was envisioned wherein the flow would be 
continuously re-oxygenated along the flow direction. This 
would enable the sustaining of the tissue at a comparably 
Fig. 5  a Oxygen concentration volume plot of the cylindrical PDMS 
flow-through Perfusion Device utilising a 95% oxygen saturated flow 
rate of 10 μL  min−1 to maintain a 250 μm thick and 4 mm wide cylin-
drical PCLS (indicated with white lines). b Oxygen tensions within 
the tissue at mid-height for cylindrical flow-through device. c Oxygen 
concentration volume plot for needle intra-perfusion device utilising 
a flow rate of 1 mL  min−1 to maintain a 1 mm thick and 8 mm wide 
cylindrical PCLS (30° section shown). d Oxygen tensions within the 
tissue at mid-height for needle device. e Oxygen concentration vol-
ume plot of the glass chamber perfusion device utilising a flow rate of 
2 μL  min−1 to maintain a 4  mm3 PCLS (Indicated with white lines). 
f Oxygen tensions within the tissue at mid-height for chamber perfu-
sion device. The green shaded regions on the line plots indicates the 
location of the in vivo oxygen tension range as found in the liver (col-
our figure online)
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lower medium flow rate as compared to a compatible non-
replenishing gas impermeable device. This allows for a 
tighter control of the tissue oxygen tension levels and would 
circumvent the imposition of steep tissue oxygen tension 
gradients along the flow direction. To achieve the afore-
mentioned properties, the device was centred around two 
PDMS gas exchange membranes with the PCLS suspended 
mid-flow within a nylon mesh carrier. Fine control of the 
oxygen tension could be achievable by altering the composi-
tion of the surrounding atmosphere and the flow rate. The 
oxygen concentration volume plot of the device revealed 
near homogeneous oxygen tension levels across the tissue 
with the exception being at the slice edges, where a steep 
increase was observed (Figs. 6 and 7). This oxygen tension 
gradient is based on the fact that the tissue slice edges would 
inevitably experience significantly higher oxygen tensions, 
due to the discontinuity in the balance between mass trans-
port and cellular consumption. This design approach was 
experimentally realised as shown in Figs. 1, 2 and ESI2-4. 
3.4  Comparison of simulation results 
of the PCLS‑based microfluidic devices
The different chip designs were assessed in terms of their 
ability to maintain PCLS in physiologically relevant oxy-
gen concentration ranges. Oxygen tension ranges were 
classified into four different groups: (i) low regions hav-
ing concentrations below 0.042 mM, (ii) regions within the 
0.042–0.091 mM range experienced in vivo (Jungermann 
and Kietzmann 2000), (iii) an intermediate high range of 
0.091–0.15 mM and (iv) regions having oxygen tensions 
higher than 0.15 mM. Volume integration was performed 
over the tissues in terms of the effective concentrations and 
the resulting comparison of the devices (Fig. 8).
Mass transport issues were observed in all of the devices 
modelled, most significantly for the perfusion design 
wherein as much as 98.8% of the tissue volume fell within 
the low oxygen concentration range thus indicating a severe 
oxygen mass transport deficiency. Simulations of the flow-
through approach and piercing needles approach showed a 
larger volume percentages in the physiologically relevant 
concentrations range, i.e., 11% and 55%, respectively. The 
PDMS perfusion device displayed the largest tissue volume 
percentage within the in vivo range, among the devices from 
the literature, managing to achieve upwards of 11.4%.
Our proposed PDMS sandwich design performed signifi-
cantly better as the tight control of the oxygen mass transport 
within the device was capable of maintaining approximately 
43% of tissue within this range. However, this design had 
the highest tissue volume percentage with a value of 23% 
falling within the intermediate oxygen range, and the second 
highest occupying the high range at 33%. The cause of this 
was attributed to the mass transport discontinuity formed at 
the tissue/liquid interfaces at the edges of the tissue (Figs. 6 
and 7). In comparison, relatively high proportions of the 
tissue volumes in the PDMS perfusion and piercing needle 
designs were also found to occupy regions within the high 
oxygen concentration range corresponding to 65% and 24%, 
respectively.
Fig. 6  a PDMS sandwich chip with the PCLS suspended between 
two PDMS membranes in a nylon mesh carrier. b Oxygen concentra-
tion plot of the device utilising an external gas atmosphere of 92% 
O2 and a flow rate of 4 μL  min−1. The 150-μm thick PCLS is sus-
pended in a nylon mesh carrier between two PDMS gas exchange 
membranes. A quarter of the device is shown (Symmetry in the longi-
tudinal and tangential direction)
Fig. 7  Simulation of the oxygen tensions of a tissue slice incubated in 
the PDMS sandwich device as plotted along the length of the slice at 
the midheight. The device was operated with an external gas atmos-
phere of 92%  O2 and a flow rate of 4 μL  min−1
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3.5  Operating parameters for proposed device
The device geometry derived from the COMSOL model-
ling (Figs. 6 and 7) was further investigated. As both the 
flow velocity and the applied gas atmospheres will impact 
the effective oxygen tensions experienced within an incu-
bated PCLS, a sweep was conducted over these parameters 
to identify a suitable operating range for the device. The 
parameter combinations were evaluated based on the vol-
ume percentage of the PCLS which would be maintained 
within the physiological range (0.042–0.091 mM). As can 
be seen from the contour plot (Fig. 9), the optimum region 
which corresponded to a tissue volume of approximately 
42% was found for flow rates of 0.5 μL  min−1 combined 
with an atmosphere consisting of 80–90% oxygen. The usage 
of slower flow rates combined with high external oxygen 
atmospheres has the effect of essentially uncoupling the 
horizontally directed oxygen mass transport flux from the 
inlet flow, whilst maintaining a high vertical flux of oxygen 
from the PDMS membranes located along the top and bot-
tom of the device.
3.6  Experimental data from proposed liver tissue 
device
The device geometry derived from the modelling was real-
ised as described in the experimental section (Figs. 1 and 
2, ESI2–4). Initial leak testing of the manufactured device 
with a red dye testing solution successfully demonstrated the 
sealing capabilities of the PDMS gas exchange membranes 
(figure S.4.1). Liver tissue sections were prepared as detailed 
in the materials and methods and loaded into the device. The 
performance of the proposed device was compared against a 
static conventional tissue slice well plate approach by deter-
mining the amount of LDH retained in tissues following 
72 h of incubation. The LDH levels found in the chips were 
approximately 30% and 16% of the levels of their respective 
PICMORG50 incubated controls, suggesting a lower level of 
viability (Fig. 10). However, these data must be considered 
preliminary as only two independent experiments were set 
up and there is a high level of variability in either set-up. 
Furthermore, there are well-known limitations regarding 
the measurement of LDH such as the release of enzyme 
inhibitors and interference from components of the media, 
thus a number of other such assays have been developed 
over the past years (Hattersley et al. 2008). Future studies 
will combine a number of these, alongside a time course of 
LDH release.
4  Conclusions
Mass transport of oxygen within tissue/organ-on-chip 
devices is an important parameter to achieve optimal main-
tenance and life-like conditions. We have investigated the 
suitability of several PCLS microfluidic devices for the 
adequate maintenance of oxygen mass transport using COM-
SOL simulations. This has led to the development of a novel, 
optimised, design to provide satisfactory in vivo oxygenation 
conditions within an organ-on-a-chip system. Simulations 
found that the proposed device was capable of maintaining 
43% of the tissue volume within the physiological range of 
Fig. 8  Evaluation of chips based 
on calculated percentage of 
tissue occupying regions within 
the physiological range found 
in liver (0.042–0.091 mM), 
as well as those within low 
(< 0.042 mM), intermediate 
(0.091–0.15 mM) and high 
range oxygen concentrations 
(> 0.15 mM)
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Fig. 9  COMSOL simulation 
for the evaluation of the impact 
of the flow rate and oxygen 
gas composition upon the 
maintenance of the PCLS. a 
Illustration of the simulation 
geometry showing the position-
ing of the PCLS within the chip 
relative to the PDMS breathing 
windows. The PMMA frames 
of the chip and tissue unit are 
shown in grey and the nylon 
mesh is also coloured in grey. 
b Contour plot highlighting the 
interdependence of the inlet 
flow velocities and the applied 
oxygen atmospheres upon the 
effective oxygen tension experi-
enced within a PCLS incubated 
in PDMS sandwich device. 
This simulation was conducted 
based on the assumption that 
the breathing window had an 
infinite width. Calculated values 
display the tissue volume per-
centages which are maintained 
in physiological range of the 
liver (0.042–0.091 mM) (colour 
figure online)
Fig. 10  Release of LDH into the 
effluents collected from PCLS 
incubated in PDMS sandwich 
device using a flow rate of 8 μL 
 min−1 and PICMORG50 well 
plate controls run in parallel 
over a period of 72 h
Microfluidics and Nanofluidics           (2021) 25:35  
1 3
Page 11 of 12    35 
the liver against 18% for the best performing device reported 
in the literature. The optimised device was then fabricated 
and tested for LDH release to confirm its functioning. It 
would be possible to further increase the mass transfer 
capacity of the device by decreasing the channel height or 
increasing the gas atmosphere or adding oxygen carriers 
to the media. These simulation results form the basis for a 
greater understanding of not just the challenges involved in 
designing organ-on-a-chip devices, but also highlight issues 
that would arise from the incorporation of additional organs, 
as research progresses towards complete human-on-a-chip 
model systems.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s10404- 021- 02434-x.
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